Skip to content

Anakinra exposure and conditional CRP turnover

Apparent subcutaneous anakinra exposure inhibits empirical CRP production. Fixed responder and waning-sensitivity groups distinguish sustained suppression from rebound under a constant or PK-derived concentration driver.

Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes ↗
Exploration notes · What are you exploring?

Notes stay on this browser.

MODEL IN MOTION 18 sec

How do response and resistance contexts change the modeled CRP signal?

Run settings

Run location

Explore this model

Choose a scenario, adjust inputs, and run the simulation.

10 kg, 2 mg/kg/day apparent SC

How does bodyweight-projected apparent SC exposure change under a fixed daily administered dose?

0–720 h

Scenario details

10 kg, 2 mg/kg/day apparent SC

How does bodyweight-projected apparent SC exposure change under a fixed daily administered dose?

Readouts

PK derived anakinra concentration · mg/L
Apparent plasma PK concentration central/(V/F); zero in constant-driver cases without SC dosing.
Conditional crp concentration · mg/L
Fixed group baseline times normalized CRP response; empirical biomarker output, not patient prediction.

Study purpose

  • How does bodyweight-projected apparent SC exposure change under a fixed daily administered dose?

Assumptions

  • Uses fixed effects without individual or population variability.
  • Clearance and volume are apparent CL/F and V/F. Physical bioavailability is unknown.
  • Baseline groups are fixed scenarios, not mixture probabilities. Waning sensitivity is not resistance prevalence.
  • Imposed concentration drives CRP directly, without PK or exposure outputs. Clearance and absorption affect SC scenarios only.
  • Ranges are exploratory. Editing clearance alone does not simulate a weight change; absorption and turnover span 0.5–1.5× defaults, and sensitivity loss spans 0–1.5× RESI.
  • Weight is set by the starting configuration. Clearance edits leave dose and volume unchanged.
  • No complete source figure panel is reproduced. Calculations use the rounded Table 1 coefficient set. Literal Table 2 uncertainty entries and reported group proportions are retained as source references; they do not establish fitted uncertainty or mixture probabilities for this implementation.
  • Changing start time resets initial states and omits earlier doses. Observations retain their before- or after-dose timing.
  • Long-term trajectories are model extrapolations without observed long-term validation.

Reference data

  • Patient observations, between-occasion variability, the mixed-effects fit, and prediction intervals have not been reproduced.

Inputs changed since the displayed result. Run to update the comparison.

Loading starting example…

Edit inputs

Simulation time
h
h
720 → 168

Time between reported samples.

h
6 → 1

2 changes · Variation 1

Continue in the background and keep the result.

Biology

Apparent subcutaneous anakinra exposure inhibits empirical CRP production. Fixed responder and waning-sensitivity groups distinguish sustained suppression from rebound under a constant or PK-derived concentration driver.

Apparent subcutaneous anakinra exposure inhibits empirical CRP production. Fixed responder and waning-sensitivity groups distinguish sustained suppression from rebound under a constant or PK-derived concentration driver.

Model details

9 parameters · 6 states · 6 equations · 9 derived outputs

Classification & API access
Therapeutic
anakinra
Modality
Other biologic or therapeutic modality
Target
IL1R1
Disease / scope
systemic juvenile idiopathic arthritis, autoinflammatory syndromes
ParameterDefaultUnitDescription
Baselinebaseline141mg/LFixed group baseline CRP, not fitted individual baseline. Envelope covers frozen private cases, not public scan or fitting bounds.
C50c500.03mg/LConcentration for half initial inhibition of CRP production. Envelope covers frozen private cases, not public scan or fitting bounds.
Systemic clearancecl6.24L/hApparent clearance CL/F, projected from source bodyweight; physical bioavailability unknown. Exploratory control; interpretation depends on the selected context.
Imposed PD concentrationconstant_c0mg/LExternally imposed PD concentration only when mode is one. Exploratory control; interpretation depends on the selected context.
Absorption rate constantka0.381/hFirst-order SC absorption rate. Exploratory control; interpretation depends on the selected context.
Loss of effect sensitivitykresi01/hDecay rate of remaining drug-effect sensitivity; zero for RESP and 0.0048/day for RESI. Exploratory control; interpretation depends on the selected context.
Crp turnover ratektr0.001751/hEmpirical CRP turnover rate, converted from day to hour. Exploratory control; interpretation depends on the selected context.
Modemode0—Fixed diagnostic switch: zero uses PK-derived concentration, one supplies constant_c. Intermediate mixtures are unqualified. Envelope covers frozen private cases, not public scan or fitting bounds.
Central distribution volumevc65.2LApparent volume V/F, projected from source bodyweight; physical distribution volume unidentified. Envelope covers frozen private cases, not public scan or fitting bounds.

Related models

Feedback: helpdesk@unibiointelligence.com.

Ubi Biologics